Citeline and Norstella Complete Merger to Form $5 Billion Global Pharma Technology Company

With more than 1,600 employees worldwide, the new organization is now one of the largest providers of pharmaceutical information solutions on the market.

YARDLEY, Pennsylvania, November 1, 2022 /PRNewswire/ — Norstella, a global leader in providing end-to-end solutions that make it easier for patients to access lifesaving therapies, announced the completion of its merger with Citeline (formerly Pharma Intelligence), a leader in the clinical trial information.

Upon closing, the $5 billion global company is now one of the largest providers of pharmacy intelligence solutions in the market, with more than 1,600 employees across the five brands that make up Norstella: Evaluate, MMIT, Panalgo, The Dedham Group, and now Citeline.

This merger will allow Norstella to prioritize rapid innovation to help guide life science companies through the drug development process, so patients can get to therapies faster.

“We believe that patient access begins with identifying unmet needs and does not end until a patient has therapy in hand,” said Mike Gallup, CEO of Norstella. “As the industry moves towards highly targeted therapies focused on smaller patient populations, our customers need solutions that provide actionable answers to critical business questions to help bring drugs to market faster – helping thus patients to receive treatment earlier. »

From the clinical discovery process to commercialization, pharmaceutical manufacturers are overwhelmed with data and inundated with questions regarding the application of real-world data, understanding disease burden, communicating clinical effectiveness of a drug, the revelation of an unexpected positive clinical result or the quantification of the consequences of a delayed therapy on the market.

As a combined organization, Norstella’s solutions will enable pharmaceutical industry players to quickly identify unmet clinical needs, design clinical trials with informed endpoints that support downstream reimbursement decisions, and accurately identify patients eligible for clinical trials. Panalgo’s Instant Health Data (IHD) platform, which can ingest clinical trials and real-world data from Citeline, MMIT data on policies, restrictions and patient labs, and clinical pathway data and real-world evidence from The Dedham Group, is a good example of this – all of this data can be leveraged to quickly answer key questions around the patient journey, payer reimbursement, and safety and security. effectiveness of therapeutic products.

“This union is an opportunity for Citeline and Norstella to further their shared mission of making therapies available to patients who need them,” said Jay NadlerExecutive Chairman of Norstella and Ramsey Hashem, CEO of Citeline. “We feel the urgency to make an impact, and we are convinced that we can bring innovation that will change the lives of patients”

Gallup added, “A key philosophy at Norstella is to innovate in partnership with our customers; we will continue to ask our customers where a gap is and how we can fill it. Together, we aim to create a more innovative and accessible healthcare market for everyone. »

About Norstella

At Norstella, our mission is simple: to help patients access therapies that save lives. Norstella is made up of several leading organizations – Citeline, Evaluate, MMIT, Panalgo and The Dedham Group, which have come together to offer a full range of pharmaceutical consulting services and solutions. As a single organization, Norstella provides life science customers with the tools and expertise to overcome challenges at every stage of the drug development cycle, from pipeline to patient. For more information, visit Norstella and follow us on LinkedIn.

About Citeline

Citeline (formerly Pharma Intelligence) offers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-centric solutions and services provide and analyze the data used to make clinical, business and regulatory decisions and create real-world growth opportunities.

Our international teams of analysts, journalists and consultants are attentive to the pharmaceutical, biomedical and medico-technical industries, and cover all aspects of these sectors thanks to their specialized knowledge: the main diseases, clinical trials, R&D and drug approvals, market forecasts, etc. To learn more about one of the world’s most trusted life science partners, visit Citeline.

Media contacts

Norstella
Melody Udell | Director, Communications
1 312-618-5968 | melody.udell@norstella.com

Citeline
Blair Dawson | Vice President, Vice President, Communications and Employee Engagement
1 919-413-4616 | blair.dawson@informa.com

Quote View original content:https://www.prnewswire.com/news-releases/citeline-et-norstella-complete-their-merger-to-form-a-global-pharmaceutical-technology-company-weighing-5- billion-dollars-301665110.html

Photo credit: DepositPhotos

Leave a Comment